If you have a certain type of multiple sclerosis (MS), your doctor might suggest Gilenya (fingolimod) as a treatment option for you. Gilenya is a prescription medication that’s used to treat the ...

Gilenya may also be prescribed to treat clinically isolated syndrome (CIS). People with CIS often (but not always) develop MS later on. If you and your doctor agree that Gilenya is working well ...

Specifically, patients taking Gilenya had a more than four-times greater likelihood of achieving NEDA across these four key measures (odds ratio 4.41; 95% CI 3.03-6.42; p NEDA is currently defined ...

Novartis has updated the prescribing information for Gilenya (fingolimod), a once daily oral therapy indicated to reduce the number of relapses and slow disability progression in patients with ...

Federal regulators granted approval for Novartis to begin selling Gilenya, a new oral treatment for relapsing multiple sclerosis, the company said Wednesday. Gilenya works by reducing the ...

ZURICH – Novartis AG said on Monday its drug Gilenya failed to meet its main goal in a late-stage study as a treatment for primary progressive multiple sclerosis (PPMS). Results of the Phase III ...

Novartis AG’s Gilenya multiple sclerosis pill lost market share for the first time in January, following the deaths of some patients soon after taking the first pill available for the disease in ...

For high-flying pills from Biogen (Tecfidera) and Novartis (Gilenya), that could mean an unwelcome comedown. It definitely means the coming market-share battle will grow even more competitive than ...

A patient taking Novartis AG’s Gilenya multiple sclerosis pill contracted a potentially deadly brain infection, adding to concern that the medicine may lose ground to a competing product.

Novartis AG's Gilenya multiple sclerosis pill lost market share for the first time in January, following the deaths of some patients soon after taking the first pill available for the disease in ...

It will not be the most expensive but it will not be the cheapest – a very effective drug at the same list price as Gilenya.” When NICE assessed Gilenya back in 2012, it said the drug costs ...